This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Browse

7 8 Dihydroxyflavone

Naturally occurring flavonoid that selectively activates TrkB — the BDNF receptor — and acts as an orally available BDNF mimetic.

Aliases (4)
7 · 8-DHF · Tropoflavin · R7
TYPICAL DOSE
10-30 mg orally per day
Daily
ROUTE
CYCLE
STORAGE

Overview

What is 7 8 Dihydroxyflavone?

7,8-Dihydroxyflavone (7,8-DHF) is a small-molecule flavone that crosses the blood-brain barrier and acts as a selective TrkB receptor agonist — effectively mimicking BDNF signaling. It is investigational in humans, widely studied in rodent models of neurodegeneration, depression, and brain injury.

Key Benefits

Mimics BDNF action to support synaptic plasticity, neurogenesis, and dendritic spine density; shows preclinical benefit in Alzheimer's, Parkinson's, depression, traumatic brain injury, and learning/memory paradigms.

Mechanism of Action

Selective TrkB receptor agonist that triggers TrkB autophosphorylation and downstream PI3K/Akt and MAPK/ERK signaling, mirroring endogenous BDNF activity. Promotes synaptic plasticity and protects neurons from apoptotic stress.

Pharmacokinetics

·
PeakHalf-life
Approximate curve — visual aid only, not data-precise PK

What to Expect

  • Week 1
    Tolerability and dose-response.
  • Week 2-4
    Early effect window.
  • Week 4-8
    Peak benefit assessment.
  • Week 8+
    Cycle decision point.

Side Effects & Safety

  • Common (>10%): Sparse data; mild GI upset reported in some users at higher doses.
  • Less common (1-10%): Headache, mild fatigue, vivid dreams.
  • Rare-serious (<1%): Theoretical concern for chronic TrkB overactivation (long-term safety unknown in humans). Cancer risk theoretical (BDNF/TrkB signaling implicated in some tumor proliferation) but unconfirmed at supplement doses.
  • Specific watch periods: Long-term safety completely uncharacterized in humans.

References

Jang et al. (2010), PNAS

pubmed.ncbi.nlm.nih.gov · 2010

original TrkB agonist characterization.

View Study

Agrawal et al. (2015), J Cereb Blood Flow Metab

pubmed.ncbi.nlm.nih.gov · 2015

TBI model improvements.

View Study

Liu et al. (2013), Mol Med

pubmed.ncbi.nlm.nih.gov · 2013

depression model efficacy.

View Study

Devi & Ohno (2012), Neuropsychopharmacology

pubmed.ncbi.nlm.nih.gov · 2012

AD mouse cognitive rescue.

View Study

Examine.com — 7,8-DHF

examine.com

evidence summary.

View Study
Was this helpful?
Your feedback shapes what we research deeper.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load
Loading…
Continue: Extended research →
Our verdict, decision matrix, deep dives, controversies, sources